Regional overviews

celebrating 20 years Other Asia

STATISTICS  
Number of products launched: 3 (2017: 0)#
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:  
0 – 2 years USD45 million
3 – 5 years USD1 million
Number of product recalls: 0 (2017: 0)
Average staff turnover: 16,5% (2017: 25,9%)
Number of work-related fatalities: 0 (2017: 0)
Number of permanent employees:  
Number of permanent employees:  

# The number of product launches has been restated as a result of the refinement of the product launch definition.

 

Other Asia comprises all Asian territories excluding China and Japan. Anaesthetics make up 46% of revenue in these countries, followed by several products in the Regional Brands category. We have active trading subsidiaries in the Philippines, Taiwan and Malaysia.

KEY COUNTRIES

Hong Kong, Philippines, Singapore, Taiwan

Contribution to Group revenue

Revenue - R'million 2018 2017 (CER) % change
Regional Brands 330 324 2
Anaesthetics 658 412 60
Thrombosis 151 166 (9)
High Potency & Cytotoxics 262 246 7
Total 1 401 1 148 22
 
  • The Asian pharmaceutical sector (excluding China and Japan) grew 7,7% and was valued at USD57 billion as at 31 December 2017.
  • The pharmaceutical sectors in Hong Kong, Philippines and Singapore (which are Aspen's key countries in "Other Asia") grew 10,0%, 1,7% and 5,3% respectively for the year ended 31 December 2017.
Source: December 2017 IMS